Momcozy Survey Finds Moms Face Biggest Challenges of Time and Breast Pump Management, When Referring to Breastfeeding and Pumping Demands
23.2.2023 09:07:00 EET | Business Wire | Press release
In a recent survey, Momcozy, the best-selling wearable breast pump brand in North America found that moms struggle with breastfeeding and breast pumping mostly due to a lack of time, space, and the right breast pump. In addition, wearable breast pumps that allow moms to pump hands-free anywhere to balance life enjoyment and nursing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230222005522/en/
Momcozy Breastfeeding and Pumping Experience Survey results (Graphic: Business Wire)
The survey was conducted from July 25th, 2022- September 13th, 2022, via Momcozy’s social media accounts and newsletter targeting North American moms, and garnered nearly 1000 responses, which found:
- Moms face many hurdles to successful breastfeeding, including breast health issues, latching problems, and isolation sense. The most common difficulty however was managing the time to pump around busy schedules, along with the difficulties of breast pump management.
- Generally, moms with wireless, wearable pumps reported more positive pumping experiences compared with their traditional breast pump counterparts.
- Most respondents pump at home, at work, or in transit, indicating moms spend most of their time between taking care of their child, and earning income.
- In terms of the ‘craziest’ place moms ever breast pumped, the most mentioned locations included at meetings, the grocery store, parties, and restaurants. Other locations mentioned such as festivals, amusement parks and sports games indicate that for some moms, wearable breast pumps allow them greater flexibility and freedom to do things they like.
These findings suggest that every minute of breastfeeding and expressing moms counts. While expressing goals can still be difficult, wearable breast pumps allow moms to express comfortably anytime, anywhere with confidence and freedom. In short, mothers have little time to choose when and where to express for themselves. But with a hands-free, wearable breast pump, moms can feel more secure pumping anywhere without missing out on the fun of their lives.
The Momcozy S12 Pro Wearable Breast Pump was developed with the full understanding of mothers' feeding needs. It can be seamlessly integrated into the busy schedule of mothers, providing an efficient breastfeeding experience and long battery life support to meet the needs of breastfeeding in various scenarios.“Always put moms on top” is what Momcozy has been fulfilling. Through cozy designs born from love and continuous innovation, Momcozy brings a much simpler, more relaxed, and more comfortable experience for moms globally through their pregnancy and early motherhood.
About Momcozy
Momcozy, the renowned maternity and baby brand endorsed by over 2 million moms, is the best companion for moms globally through their pregnancy and early motherhood. Centering around wearable breast pumps, Momcozy offers a wide range of products covering nursing, clothing and textile, FMCG, security, and more to accompany moms through their pregnancy and early motherhood in a more comfy and convenient way, making it the choice of Gen Z and millennial moms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005522/en/
Contact information
Marketing Dept.
Ella Zheng
1-855-322-1777(Mon.-Fri. 8:30am-12:00pm;1:00pm-5:30pm PST)
ella.zheng@momcozy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
